Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity

The S&P 500 slipped 0.16% to 6,816.34, the Nasdaq fell 0.59% to 23,057.41 and the Dow eased 0.09% to 48,416.57 as AI and tech weakness pressured markets and investors adopted a cautious, data‑driven stance. Kyverna Therapeutics surged over 30% on positive Phase 2 data in stiff person syndrome, Hershey rose after an analyst upgrade while Costco lagged following a downgrade, and a price‑target cut for Broadcom added to sector caution. Hedge funds continued to add to U.S. equity positions for a sixth week but gains were offset by soft China signals and Asian tech weakness; attention now turns to upcoming economic releases—especially payrolls—which could materially reshape the rate‑cut timeline and market leadership.

Analysis

The S&P 500 slipped 0.16% to 6,816.34, the Nasdaq Composite fell 0.59% to 23,057.41 and the Dow eased 0.09% to 48,416.57 as AI and broader technology weakness weighed on markets. The pullback reflects growing unease with valuations that had assumed uninterrupted momentum, a theme reinforced by a price-target cut for Broadcom that heightened sector caution. Market tone is mildly negative according to the sentiment outputs and market-impact signals were modestly constructive for selective flows.

Stock-level divergence was pronounced: Kyverna Therapeutics surged more than 30% after positive Phase 2 data in stiff person syndrome, Hershey gained on an analyst upgrade citing EPS visibility, and Costco lagged following a downgrade to Sell. Hedge funds added to U.S. equity positions for a sixth straight week, providing technical support that was, however, offset by soft signals from China and weakness in Asian tech. These dynamics are pushing investors toward names with clearer near-term earnings underwrites and away from high-growth narratives that lack visible earnings paths.

Immediate direction depends on upcoming economic releases—most notably Tuesday’s payrolls report—which could materially reshape the expected path of rate cuts and sector leadership next year. Given elevated valuation risk in AI/tech and the bifurcated market reaction, positioning should favor earnings visibility and catalyst-driven, size-controlled event trades while monitoring macro data and regional tech flows for confirmation.

Key Decisions for Investors

• Reduce or hedge concentrated AI and high-valuation tech exposure ahead of payrolls and further analyst revisions, using options or smaller position sizes
• Tilt toward names with explicit near-term earnings visibility such as defensives highlighted by analyst upgrades (for example HSY) and avoid adding to fundamentally downgraded retailers like COST
• Keep event-driven biotech exposure (for example KYTX) size-controlled for upside from clinical data, monitor payrolls and China/Asian tech signals for a market-direction cue, and only increase conviction on confirmed macro-led repricing